GLP-1 therapies are among the fastest-growing drug classes worldwide, projected to drive a $95 billion obesity market by 2030
Globally, colorectal cancer impacts 1.9 million people each year, standing as a leading cause of cancer mortality
Collaboration integrates NVIDIA accelerated computing and the NVIDIA BioNeMo platform with QIAGEN Digital Insights’ curated biomedical knowledge bases
The next-generation proteomics platform powered by Olink™ Explore HT enables simultaneous analysis of thousands of proteins from a single sample
The precision health platform integrates genetics, biomarkers, diet, and lifestyle data to deliver personalised gut health interventions and therapy support
Our company remains focused on advancing monoclonal antibody therapeutics for solid tumors, with a clear emphasis on combination immunotherapy strategies
New minimally invasive biomarker test enables earlier diagnosis and improved clinical decision-making, aligned with global guidelines
The newly formed SAB will provide strategic direction across research, clinical development, and regulatory pathways
he innovation could pave the way for early and low-cost screening of smoking exposure and second-hand smoke biomarkers
The programme features headline data from pivotal Phase III trials, including PREVAIL in gMG, KOMET in NF1-PN, and CHAMPION-NMOSD, alongside real-world evidence supporting established therapies
Subscribe To Our Newsletter & Stay Updated
